Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 89

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 9A
Chunk 89
---
 will not be prevented or detected on a timely basis.
The material weakness previously identified was due to (i) the design and implementation of appropriate segregation of duties to separate
the roles of authorizing, initiating, and recording transactions or reviewing transactions for the completeness and accuracy of contracts
with financial reporting implications and (ii) the Company lacking sufficient appropriate accounting and reporting knowledge to effectively
perform review controls surrounding technical accounting matters. As of December 31, 2024, our principal executive officer and principal
financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the Committee
of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework - 2013. Based on this assessment and
implementation of our remediation plans, management concluded that, as of December 31, 2024, our internal controls over financial reporting
were effective.

This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal
control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting
firm pursuant to the exemption provided to issuers that are not “large accelerated filers” nor “accelerated filers”
under the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as issuers that are “emerging growth companies”
under the JOBS Act.

-35-

Changes
in Internal Control Over Financial Reporting

There
were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2024 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM
9B. OTHER INFORMATION

During
the quarter ended December 31, 2024, none of our directors or executive officers adopted, modified, or terminated a “Rule 10b5-1
trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Rule 408 of Regulation
S-K.

ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

Not
applicable.

PART
III

ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The
information required by this item is incorporated by reference from the information contained in our Definitive Proxy Statement to be
filed with the Securities and Exchange Commission in connection with the